JP6759203B2 - 薬物及び他の物質の送達のための経口組成物 - Google Patents
薬物及び他の物質の送達のための経口組成物 Download PDFInfo
- Publication number
- JP6759203B2 JP6759203B2 JP2017527546A JP2017527546A JP6759203B2 JP 6759203 B2 JP6759203 B2 JP 6759203B2 JP 2017527546 A JP2017527546 A JP 2017527546A JP 2017527546 A JP2017527546 A JP 2017527546A JP 6759203 B2 JP6759203 B2 JP 6759203B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- general formula
- formula
- free fatty
- monoglyceride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BQDXCOFFRFQPIT-UHFFFAOYSA-O CC(CCCOC)COP(OC)(OCC[NH+](C)C)=O Chemical compound CC(CCCOC)COP(OC)(OCC[NH+](C)C)=O BQDXCOFFRFQPIT-UHFFFAOYSA-O 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035393P | 2014-08-09 | 2014-08-09 | |
| US62/035,393 | 2014-08-09 | ||
| PCT/US2015/044501 WO2016025401A1 (en) | 2014-08-09 | 2015-08-10 | Oral composition for delivery of drugs and other substances |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017524036A JP2017524036A (ja) | 2017-08-24 |
| JP2017524036A5 JP2017524036A5 (enExample) | 2018-09-20 |
| JP6759203B2 true JP6759203B2 (ja) | 2020-09-23 |
Family
ID=55304531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017527546A Active JP6759203B2 (ja) | 2014-08-09 | 2015-08-10 | 薬物及び他の物質の送達のための経口組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9872908B2 (enExample) |
| EP (1) | EP3177279B1 (enExample) |
| JP (1) | JP6759203B2 (enExample) |
| KR (2) | KR102507657B1 (enExample) |
| CN (1) | CN107072967B (enExample) |
| AU (1) | AU2015301952B2 (enExample) |
| CA (1) | CA2956960C (enExample) |
| DK (1) | DK3177279T3 (enExample) |
| ES (1) | ES3033965T3 (enExample) |
| IL (1) | IL250394B (enExample) |
| WO (1) | WO2016025401A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015301952B2 (en) * | 2014-08-09 | 2020-12-03 | Avanti Polar Lipids, Inc. | Oral composition for delivery of drugs and other substances |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2514755A1 (fr) | 1981-10-21 | 1983-04-22 | Rhone Poulenc Chim Base | Procede de preparation de l'anhydride acetique |
| ZA831053B (en) * | 1982-02-17 | 1985-03-27 | Ciba Geigy Ag | Lipids in aqueous phase |
| DE3374837D1 (en) * | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| EP0102324A3 (de) * | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| IE59067B1 (en) * | 1985-04-02 | 1993-12-15 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
| US4874795A (en) * | 1985-04-02 | 1989-10-17 | Yesair David W | Composition for delivery of orally administered drugs and other substances |
| JPH01274830A (ja) * | 1988-04-28 | 1989-11-02 | Asahi Denka Kogyo Kk | 安全で且つ高度な界面活性を有する脂質組成物 |
| JPH03127731A (ja) * | 1989-10-12 | 1991-05-30 | Yakult Honsha Co Ltd | ビタミンeの可溶化方法およびビタミンe製剤 |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US20030235595A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent |
| EP2062574B1 (en) * | 2006-09-08 | 2015-03-25 | Kaneka Corporation | Composition comprising reduced coenzyme q10 and lysolecithin |
| EP2526971A1 (en) * | 2011-05-25 | 2012-11-28 | ArisGen SA | Mucosal delivery of drugs |
| AU2015301952B2 (en) * | 2014-08-09 | 2020-12-03 | Avanti Polar Lipids, Inc. | Oral composition for delivery of drugs and other substances |
-
2015
- 2015-08-10 AU AU2015301952A patent/AU2015301952B2/en active Active
- 2015-08-10 WO PCT/US2015/044501 patent/WO2016025401A1/en not_active Ceased
- 2015-08-10 KR KR1020227016492A patent/KR102507657B1/ko active Active
- 2015-08-10 EP EP15832041.6A patent/EP3177279B1/en active Active
- 2015-08-10 CN CN201580049486.0A patent/CN107072967B/zh active Active
- 2015-08-10 US US14/822,289 patent/US9872908B2/en active Active
- 2015-08-10 ES ES15832041T patent/ES3033965T3/es active Active
- 2015-08-10 JP JP2017527546A patent/JP6759203B2/ja active Active
- 2015-08-10 DK DK15832041.6T patent/DK3177279T3/da active
- 2015-08-10 KR KR1020177006233A patent/KR20170033442A/ko not_active Ceased
- 2015-08-10 CA CA2956960A patent/CA2956960C/en active Active
-
2017
- 2017-02-01 IL IL250394A patent/IL250394B/en active IP Right Grant
- 2017-11-08 US US15/807,389 patent/US10463738B2/en active Active
-
2019
- 2019-10-31 US US16/669,825 patent/US11510985B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR102507657B1 (ko) | 2023-03-08 |
| KR20220070551A (ko) | 2022-05-31 |
| IL250394A0 (en) | 2017-03-30 |
| IL250394B (en) | 2021-05-31 |
| KR20170033442A (ko) | 2017-03-24 |
| AU2015301952B2 (en) | 2020-12-03 |
| CA2956960C (en) | 2023-10-24 |
| EP3177279B1 (en) | 2025-06-04 |
| CN107072967B (zh) | 2021-01-12 |
| WO2016025401A1 (en) | 2016-02-18 |
| US9872908B2 (en) | 2018-01-23 |
| CN107072967A (zh) | 2017-08-18 |
| US11510985B2 (en) | 2022-11-29 |
| DK3177279T3 (da) | 2025-08-18 |
| AU2015301952A1 (en) | 2017-02-16 |
| EP3177279A1 (en) | 2017-06-14 |
| ES3033965T3 (en) | 2025-08-11 |
| CA2956960A1 (en) | 2016-02-18 |
| JP2017524036A (ja) | 2017-08-24 |
| US20180064813A1 (en) | 2018-03-08 |
| EP3177279A4 (en) | 2018-04-18 |
| US20200188518A1 (en) | 2020-06-18 |
| US20160166699A1 (en) | 2016-06-16 |
| US10463738B2 (en) | 2019-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5753157B2 (ja) | 親水性薬剤の自己マイクロエマルジョン化経口医薬組成物およびその調製方法 | |
| BR112017010657B1 (pt) | Cápsulas moles de calcifediol | |
| CN1909891A (zh) | 药用组合物的微乳液 | |
| JP2019510048A (ja) | 週1回又は隔週1回の投与に適したリラグルチドの粘弾性ゲル | |
| CN1582142A (zh) | 布洛芬盐乳化剂和包含其的霜剂制剂 | |
| JP6759203B2 (ja) | 薬物及び他の物質の送達のための経口組成物 | |
| US10806742B2 (en) | Liquid phospholipid-containing compositions for the preparation of pharmaceuticals | |
| US20210196836A1 (en) | Formulation of nanostructured gels for increased agent loading and adhesion | |
| US10960016B2 (en) | Capsules containing high doses of krill phospholipids | |
| JP5936609B2 (ja) | キナーゼインヒビターの経口製剤 | |
| KR101096429B1 (ko) | 안정성이 향상된 아세클로페낙의 경구용 연질캅셀제 | |
| JP7149611B2 (ja) | 薬物を保持した非水系組成物およびその製造方法 | |
| EP3197499B1 (fr) | Administration par voie orale d'au moins une substance active pharmaceutique et/ou antigénique | |
| RU2742650C2 (ru) | Фармацевтический состав | |
| US20240315968A1 (en) | Sustained release cancer therapeutics formulations | |
| JP5513827B2 (ja) | 外用医薬組成物 | |
| US20180028470A1 (en) | Curcumin-based pharmaceutical compositions and methods for fabricating thereof | |
| CN116367860A (zh) | 制备脂质体的方法 | |
| WO2015045037A1 (ja) | カプセル製剤 | |
| WO2015150959A1 (en) | Oral liquid pharmaceutical compositions comprising methyldopa or salts thereof | |
| JP2013199458A (ja) | カプセル製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180808 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180808 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190628 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200324 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200519 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200804 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200902 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6759203 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |